Work

Randomized phase II study of the safety, efficacy, and immune response of GVAX pancreas (with cyclophosphamide) and CRS-207 with or without nivolumab in patients with previously treated metastatic pancreatic adenocarcinoma (STELLAR).

Year: 2016

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2016.34.4_suppl.tps486

Authors: Dung T. Le, Todd S. Crocenzi, Jennifer N. Uram, Eric R. Lutz, Dan Laheru, Elizabeth A. Sugar, Robert H. Vonderheide, George A. Fisher, Andrew H. Ko, Aimee L. Murphy, Katherine McDougall, Sandy Ferber, Dirk G. Brockstedt, Elizabeth M. Jaffee

Institutions: Johns Hopkins University, Sidney Kimmel Comprehensive Cancer Center, Providence Portland Medical Center, University of Pennsylvania, Stanford Medicine, Stanford University, UCSF Helen Diller Family Comprehensive Cancer Center, Aduro BioTech (United States)

Language: English

Topic: Pancreatic and Hepatic Oncology Research

Subfield: Oncology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2591460798

Cites:

Cited by: 13

Related to: 10